Breye Therapeutics has closed an oversubscribed €67.5M Series A to develop oral treatments for retinal diseases.
The Copenhagen-based clinical-stage biopharmaceutical company focuses on early treatment, aiming to reach patients before vision loss advances. Mission BioCapital and existing investor Novo Holdings co-led the round. Sound Bioventures returned, and new investors joined.
Retinal disease is normally treated with injections into the eye, a burden for patients and clinics alike. Breye’s pitch is that a pill can change how early and how often people get treated, widening the pool of patients who can start therapy.
The raise stands out in a European venture market that has grown more selective. Investors have concentrated capital in fewer, larger deals, especially in life sciences where clinical risk is high and timelines are long.
Danish biotech has drawn steady backing from Novo Holdings, the investment arm tied to Novo Nordisk, which anchors many local rounds. That ecosystem gives Copenhagen firms access to patient capital that rivals in smaller markets lack.
Breye now faces the expensive part. The Series A buys trials, not approvals, and the next few years will decide whether an oral retinal drug can clear the clinical and regulatory bar.
